Genetics in melanoma

Israel Medical Association Journal

Volumn 6, Issue 12, 2004, Pages 774-777

  Stahl, Shy ^c   Bar Meir, Eran ^a,c   Friedman, Eitan ^a,b   Regev, Eli ^a   Orenstein, Arie ^a   Winkler, Eyal ^a  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c NONE

Author keywords

CDK4; CDKN2A; Genetics; Inherited predisposition; Malignant melanoma

Indexed keywords

BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYTOCHROME P450 2D6; DEBRISOQUINE 4 HYDROXYLASE; EPIDERMAL GROWTH FACTOR; GLUTATHIONE TRANSFERASE; MELANOCORTIN 1 RECEPTOR; VITAMIN D RECEPTOR;

ARTICLE; CANCER GENETICS; CANCER RISK; CELL CYCLE; CELL DIVISION; FAMILY HISTORY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MELANOMA; MOLECULAR MECHANICS; RADIATION EXPOSURE; RISK ASSESSMENT; RISK FACTOR; ULTRAVIOLET RADIATION;

CYTOCHROME P-450 CYP2D6; EPIDERMAL GROWTH FACTOR; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; MELANOMA; PENETRANCE; RECEPTOR, MELANOCORTIN, TYPE 1; RECEPTORS, CALCITRIOL;

EID: 10644297320     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Bulliard JL. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer 2000;85:627-32.
3. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;181:193-201.
4. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-52.
5. Kopf AW, Hellman LJ, Rogers GS, et al. Familial malignant melanoma. JAMA 1986;256:1915-19.
6. Hayward N. Genetics of melanoma predisposition. Oncogene 2003;22: 3053-62.
7. Smith-Sorensen B, Hovig E. CDKN2A (p16INK4A) somatic and germline mutations. Hum Mutat 1996;7:294-303.
8. Aitken J, Welch J, Duffy D, et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-52.
9. Stenson PD, Ball EV, Mort M, et al. The Human Gene Mutation Database (HGMD): 2003 Update. Hum Mutat 2003;21:577-81.
10. Pollock PM, Spurr N, Bishop T, et al. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat 1998;11:424-31.
11. Yakobson E, Shemesh P, Azizi E, et al. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 2000;8:590-6.
12. Scott RJ, Vajdic CM, Armstrong BK, et al. BRCA2 mutations in a population-based series of patients with ocular melanoma. Int J Cancer 2002;102:188-91.
13. Iscovich J, Addulrazik M, Cour C, et al. Prevalence of the BRCA2 6174delT mutation in Israeli uveal melanoma patients. Int J Cancer 2001;98:42-4.
14. Bishop DT, Demenais F, Goldstein A, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
15. Newton-Bishop JA, Wachsmuth RC, Harland M, et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000;114:28-33.
16. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-4.
17. Vasen HFA, Gruis NA, Frantis RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19′ deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809-11.
18. Kumar R, Smeds J, Berggren P, et al. A single nucleotide polymorphism in the 3′ untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 2001;95:388-93.
19. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-30.
20. Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86.
21. Harding RM, Healy E, Ray AJ, et al. Evidence for variable selective pressures at MC1R. Am J Hum Genet 2000;66:1351-61.
22. Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-73.
23. Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359:397-401.
24. Kanetsky PA, Holmes R, Walker A, et al. Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 2001;10:509-13.
25. Strange RC, Ellison T, Ichii-Jones F, et al. Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 1999;9:269-76.
26. 3, α- melanocyte stimulating hormone, and β-estradiol. J Invest Dermatol 1988;91:593-8.
27. Hutchinson PE, Osborne JE, Lear JT, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000;6:498-504.
28. Kefford RF, Mann GJ. Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol 2003;15:157-61.